期刊文献+

应用FibroTouch技术评价2型糖尿病患者肝脏脂肪变和纤维化程度及二者相关性 被引量:4

Evaluation of liver steatosis and fibrosis in patients of type 2 diabetes mellitus and correlation between liver steatosis and fibrosis by FibroTouch technique
下载PDF
导出
摘要 目的:应用FibroTouch技术评价2型糖尿病(T2DM)患者肝脏脂肪变和纤维化程度及二者相关性。方法:将92例T2DM患者按病程分为两组:病程>10年(A组)46例;病程≤10年(B组)46例,正常对照组(C组)46例。应用FibroTouch技术对肝脏脂肪衰减参数和肝脏硬度值进行检测,获得肝脏脂肪衰减参数和肝脏硬度值。结果:A组和B组肝脏脂肪衰减参数和肝脏硬度值均明显大于C组(P均<0.05);A组肝脏脂肪衰减参数小于B组(P<0.05);A组肝脏硬度值大于B组(P<0.05)。A组、B组脂肪衰减的程度较C组增加(P均<0.05);A组脂肪衰减的程度较B组减低(P<0.05);A组、B组肝脏硬度的程度较C组增加(P均<0.05),A组肝脏硬度的程度较B组增加(P<0.05)。T2DM患者肝脏脂肪变和纤维化程度之间呈明显负相关性(r=-0.81,P<0.05)。结论:FibroTouch技术可以无创、方便、客观地评价T2DM患者肝脏脂肪变和纤维化程度,具有重要的临床价值。 Objective: To evaluate the extent of liver steatosis and fibrosis in patients of type 2 diabetes mellitus(T2DM) and correlation between liver steatosis and fibrosis by FibroTouch technique. Methods: Ninety-two cases of T2DM patients were enrolled and divided into group A (46 cases, diabetic duration〉10 years) and group B (46 cases, diabetic duration≤10 years). Forty-six healthy subjects were enrolled as controls (group C). FibroTouch technique was used to measure the liver fat attenuation parameter (FAP) and liver stiffness t (LSM). Results: The FAP and LSM of group A and group B were significantly larger than those of group C (all of P〈0.05); the FAP of group A was smaller than that of group B and the LSM of group A was larger than that of group B(all P〈0.05). The degree of liver steatosis increased in group A and group B compared with that of group C(all of P〈0.05), and the degree of liver steatosis decreased in group A compared with that of group B(P〈0.05); The degree of liver stiffness increased in group A and group B compared with that of group C (all of P〈0.05), and the degree of liver stiffness increased in group A compared with that of group B(P〈0.05). There was a negative correlation be- tween liver fibrosis and steatosis (r=-0.81, P〈0.05). Conclusion: The fibrosis and steatosis of the liver in T2DM patients can be evaluated non-invasively, conveniently and objectively by FibroTouch technique, which has an important clinical value.
作者 马丽雪 张宇虹 苏本利 MA Li-xue;ZHANG Yu-hong;SU Ben-li(Department of Ultrasound,the Second Hospital of Dalian Medical University,Dalian Liaoning 116027,China)
出处 《中国临床医学影像杂志》 CAS 2018年第9期636-639,共4页 Journal of China Clinic Medical Imaging
关键词 脂肪肝 肝硬化 糖尿病 2型 超声检查 多普勒 彩色 Fatty liver Liver cirrhosis Diabetes mellitus type 2 Ultrasonography Doppler color
  • 相关文献

参考文献3

二级参考文献34

  • 1中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南[J].中国肝脏病杂志(电子版),2010,2(4):49-53. 被引量:385
  • 2袁利超,邵金华,郝美娜,李程,王贵萍,王泰龄,罗建文,白净,马安林.肝脏硬度测定仪FibroTouch与FibroScan和肝脏病理分期的相关性[J].中华肝脏病杂志,2014,22(6). 被引量:44
  • 3Leite NC,Villela-Nogueira CA,Pannain VL. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes:prevalences and correlated factors[J].{H}Liver International,2011.700-706.
  • 4Carulli L,Maurantonio M,Hebbard L. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD[J].{H}Current Pharmaceutical Design,2013.5280-5296.
  • 5Angulo P,Hui JM,Marchesini G. The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD[J].{H}HEPATOLOGY,2007.846-854.
  • 6Musso G,Gambino R,Cassader M. Meta-analysis:natural historv of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-iwasive tests for liver disease severity[J].{H}Annals of Medicine,2011.617-649.
  • 7Hossain N,Afendy A,Stepanova M. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease[J].{H}Clinical Gastroenterology and Hepatology,2009.1224-1229.
  • 8Masuoka HC,Chalasani N. Nonalcoholic fatty liver disease:an emerging threat to obese and diabetic individuals[J].{H}Annals of the New York Academy of Sciences,2013.106-122.
  • 9Juurinen L,Tiikkainen M,H(a)kkinen AM. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes[J].{H}American Journal of Physiology Endocrinology and Metabolism,2007.E829-E835.
  • 10Rudovich NN,Weickert MO,Machann J. Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease:a break of intestinal insulin resistance[J].{H}Journal of Hepatology,2010.952-953.

共引文献25

同被引文献16

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部